Yasuhiko Kita

Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis

Shunsuke Furuta, Daiki Nakagomi, Y Kobayashi et al. · JAMA · 2021 · 217 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +14

The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression

Tatsuya Atsumi, Kazuhiko Yamamoto, Tsutomu Takeuchi et al. · Annals of the Rheumatic Diseases · 2015 · 112 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +16

Selective reduction and recovery of invariant Valpha24JalphaQ T cell receptor T cells in correlation with disease activity in patients with systemic lupus erythematosus.

Yoshinori Oishi, Takayuki Sumida, Akemi Sakamoto et al. · PubMed · 2001 · 70 citations

Life Sciences, Cell Biology, Immunology +16

Expression of sequences homologous to htlv‐i <i>tax</i> gene in the labial salivary glands of japanese patients with sjögren's syndrome

Takayuki Sumida, F Yonaha, Toshiro Maeda et al. · Arthritis & Rheumatism · 1994 · 69 citations

Life Sciences, Immunology, Molecular Biology +15

Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial

Tatsuya Atsumi, Yoshiya Tanaka, Kazuhiko Yamamoto et al. · Annals of the Rheumatic Diseases · 2017 · 41 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15